GCG and Hyperglycemia: Incretin-based therapies, including DPP4is, also called gliptins, and incretin mimetics, such as GLP-1RAs, are widely used in the clinical treatment of T2D due to their ability to improve hyperglycaemia (HbA1c reduction of −2.3 ± 1.2%) [128], in association with improved survival and function of β-cells and suppression of glucagon secretion [129,130].